Rakovina Therapeutics Inc. (TSXV:RKV)
Canada · Delayed Price · Currency is CAD 0.2200
+0.0100 (4.76%)
At close: Aug 28, 2026
Rakovina Therapeutics Balance Sheet
Financials in millions CAD. Fiscal year is January - December.
Millions CAD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 0.59 | 0.3 | 1.31 | 0.44 | 0.9 | 2.81 |
Cash & Short-Term Investments | 0.59 | 0.3 | 1.31 | 0.44 | 0.9 | 2.81 |
Cash Growth | 672.77% | -77.24% | 200.87% | -51.35% | -68.10% | 40164771.43% |
Other Receivables | 0.04 | 0.06 | 0.08 | 0.02 | 0.01 | 0.07 |
Receivables | 0.04 | 0.06 | 0.08 | 0.02 | 0.01 | 0.07 |
Prepaid Expenses | 0.18 | 0.2 | 0.4 | 0.18 | 0.16 | 0.19 |
Other Current Assets | 0.08 | 0.24 | 0.47 | - | - | - |
Total Current Assets | 0.89 | 0.8 | 2.26 | 0.63 | 1.07 | 3.07 |
Other Intangible Assets | 3.31 | 3.44 | 3.98 | 4.52 | 5.05 | 5.59 |
Total Assets | 4.2 | 4.24 | 6.24 | 5.15 | 6.12 | 8.66 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 1.52 | 1.2 | 0.4 | 0.01 | 0.03 | 0.04 |
Accrued Expenses | 0.1 | 0.3 | 0.12 | 0.15 | 0.08 | 0.07 |
Current Portion of Long-Term Debt | - | 1.45 | 1.42 | - | - | - |
Total Current Liabilities | 1.62 | 2.95 | 1.94 | 0.15 | 0.11 | 0.11 |
Long-Term Debt | 3.01 | 1.15 | - | 1.33 | - | - |
Other Long-Term Liabilities | 0.13 | - | - | - | - | - |
Total Liabilities | 4.75 | 4.1 | 1.94 | 1.49 | 0.11 | 0.11 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 19.24 | 18.75 | 16.45 | 13.6 | 13.58 | 13.57 |
Additional Paid-In Capital | 5.07 | 4.84 | 2.85 | 0.91 | 0.75 | 0.49 |
Retained Earnings | -25.35 | -23.68 | -15 | -10.93 | -8.31 | -5.52 |
Comprehensive Income & Other | 0.49 | 0.24 | 0 | 0.08 | - | - |
Shareholders' Equity | -0.56 | 0.14 | 4.3 | 3.66 | 6.01 | 8.54 |
Total Liabilities & Equity | 4.2 | 4.24 | 6.24 | 5.15 | 6.12 | 8.66 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 3.01 | 2.6 | 1.42 | 1.33 | - | - |
Net Cash (Debt) | -2.42 | -2.3 | -0.11 | -0.9 | 0.9 | 2.81 |
Net Cash Growth | - | - | - | - | -68.10% | 40164771.43% |
Net Cash Per Share | -0.12 | -0.13 | -0.01 | -0.13 | 0.13 | 0.52 |
Filing Date Shares Outstanding | 24.41 | 21.15 | 14 | 7.01 | 6.98 | 6.98 |
Total Common Shares Outstanding | 24.41 | 21.15 | 14.05 | 7.01 | 6.98 | 6.98 |
Working Capital | -0.73 | -2.15 | 0.32 | 0.48 | 0.96 | 2.96 |
Book Value Per Share | -0.02 | 0.01 | 0.31 | 0.52 | 0.86 | 1.22 |
Tangible Book Value | -3.86 | -3.3 | 0.32 | -0.86 | 0.96 | 2.96 |
Tangible Book Value Per Share | -0.16 | -0.16 | 0.02 | -0.12 | 0.14 | 0.42 |